Last reviewed · How we verify
Dexmedetomidine and Midazolam
At a glance
| Generic name | Dexmedetomidine and Midazolam |
|---|---|
| Also known as | Precedex, Precedex and Dormicum |
| Sponsor | Montefiore Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Characteristic Electroencephalogram of General Anesthesia
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium (PHASE4)
- Comparison Between Two Drugs in Sedation of Upper GI Endoscopy
- Dexmedetomidine vs Midazolam in Coronary Artery By-pass Surgery (NA)
- Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial (NA)
- Comparison of Effect of Dexmedetomidine and Midazolam on Emergence Agitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine and Midazolam CI brief — competitive landscape report
- Dexmedetomidine and Midazolam updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI